ARTICLE | Company News
Arachnova Therapeutics Ltd., Mitsubishi Pharma deal
March 22, 2004 8:00 AM UTC
Arachnova received a license to develop Mitsubishi's MCI-225, a noradrenaline and serotonin reuptake inhibitor, and serotonin (5-HT3) receptor antagonist, for pain, stress urinary incontinence and f...